Skip to main content
. 2020 Jul 2;6(8):1–13. doi: 10.1001/jamaoncol.2020.2134

Table 1. Cancer Diagnosis in Male BRCA1/2 Pathogenic Variant (PV) Carriers Within CIMBA Data Set and Odds Ratios (ORs) in Predicting BRCA2 PV Carrier Status.

No. (%) Adjusted OR (95% CI)a P value
Total (N = 6902) BRCA1 (n = 3651) BRCA2 (n = 3251)
Unaffected 5526 (80.1) 3197 (87.6) 2329 (71.6) 1.00 [Reference]
Affected 1376 (19.9) 454 (12.4) 922 (28.4) 3.23 (2.81-3.70) <.001
Cases with 1 cancer diagnosis 1144 (83.1) 416 (91.6) 728 (79.0) 2.77 (2.40-3.20) <.001
Breast cancer 380 (33.2) 50 (12.0) 330 (45.3)
Prostate cancer 273 (23.9) 83 (20.0) 190 (26.1)
Cancer other than breast and prostate 491 (42.9) 283 (68.0) 208 (28.6)
Cases with 2 cancer diagnoses 206 (15.0) 36 (8.0) 170 (18.4) 7.97 (5.47-11.60) <.001
Bilateral breast cancer 24 (11.7) 0 24 (14.1)
Breast and prostate cancer 53 (25.7) 4 (11.1) 49 (28.8)
Breast cancer and cancer other than breast and prostate 59 (28.6) 8 (22.2) 51 (30.0)
Prostate cancer and cancer other than breast and prostate 69 (33.5) 23 (63.9) 46 (27.1)
Two cancers other than breast and prostate 1 (0.5) 1 (2.8) 0
Cases with 3 cancer diagnoses 26 (1.9) 2 (0.4) 24 (2.6) 19.60 (4.64-82.89) <.001
Bilateral breast and prostate cancer 5 (19.2) 0 5 (20.8)
Bilateral breast and cancer other than breast and prostate 7 (26.9) 0 7 (29.2)
Prostate cancer and 2 cancers other than breast and prostate 1 (3.8) 1 (50.0) 0
Breast, prostate, and cancer other than breast and prostate 13 (50.0) 1 (50.0) 12 (50.0)

Abbreviation: CIMBA, Consortium of Investigators of Modifiers of BRCA1/2.

a

Analyses adjusted for age at cancer diagnosis/last follow-up, country of origin, and calendar year of interview.